// App-Quantinova.ai

e18817 : Budget impact (BI) analysis of cemiplimab for first-line (1L) advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% in the United States.

Researchers

Presenter

  • Andreas Kuznik

Principal Investigators

  • Caitlin Smare

  • Chieh-I Chen

  • Meena Venkatachalam

  • Sam Keeping

  • Kokuvi Atsou

  • Yingxin Xu

  • Florence Wilson

  • Patricia Guyot

  • Keith Chan

  • Emily Glowienka

  • Gerasimos Konidaris

Medical Centers

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY, Precision HEOR, London, United Kingdom

  • PRECISIONheor,Vancouver, BC,Canada

  • Sanofi, Chilly-Mazarin, France

  • Precision Xtract, Vancouver, BC, Canada

  • Precision HEOR, Boston, MA

  • Sanofi, Reading, United Kingdom

Locations

  • United Kingdom

  • Canada

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Anaplastic lymphoma Kinase

  • Programmed death-ligand 1

  • Epidermal growth factor receptor

Drug/Treatment

  • Pembrolizumab

  • Atezolizumab

  • Durvalumab

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved